To improve the objectivity of the integration of positron emission tomography (PET), we used the conformality index (CI) to measure the goodness of fit of a given PET iso-SUV (standardized uptake value) level with the GTV defined on PET (GTV PET ) and CT (GTV CT ). Twenty-two datasets involving 20 head and neck cancer patients were identified. GTV PET and GTV CT were delineated manually. An iso-intensity method was developed to automatically segment GTV PET-ISO using (a) SUV and (b) maximum intensity thresholding (%Max), over a range of intensities. For each intensity, GTV PET-ISO was compared to GTV PET using the conformality index CI PET (and, similarly, to GTV CT using CI CT ). Comparing GTV PET to GTV PET-ISO vs comparing GTV CT to GTV PET-ISO, the average peak CI was 0.68 ± 0.09 vs 0.49 ± 0.12 (p<0.001), the optimum iso-SUV was 2.7 ± 0.7 vs 2.9 ± 1.0 (p=0. 253), and the %Max SUV was 21.8% ± 7.6% vs 23.8% ± 8.6% (p=0. 310), respectively. The radiation oncologist's volumes corresponded to a lower iso-SUV (3.02 ± 0.58 vs 4.36 ± 0.77, p < 0.001) and lower %Max SUV (24.1 ± 9.1% vs 34.3 ± 11.2%, p<0.001) than those drawn by the nuclear medicine physician. Though manual editing may still be necessary, PET iso-contouring is one method to improve the objectivity of GTV definition in head and neck cancer patients. Iso-SUV's can also be used to study the differences between PET's role as a nuclear medicine diagnostic test versus a radiation oncology treatment planning tool.
Introduction
Numerous advances in treatment planning strategies have taken place in radiation oncology. One of the more frequently incorporated strategies is the utilization of 18F-Fluoro-deoxyglucose (FDG)-PET in delineating the gross tumor volume (GTV). In addition to the traditional anatomical information provided by computer tomography (CT), the metabolic and functional aspects of FDG-PET allow for better visualization and localization of the tumor target (1). It has been shown that PET is highly accurate in staging head and neck cancers (2, 3) .
Despite the ease and usefulness of PET for staging various types of cancers, there are some notable challenges when integrating PET into radiotherapy treatment planning (4-6). These challenges include optimizing the manner in which the emission component is visualized (7) (8) , improving the image registration process (9), and increasing the accuracy and reproducibility of target volume delineation (10-11). These previous methods that have attempted to quantify PET visualization include standard uptake value (SUV) thresholds, percent maximum threshold values, target to background ratios, and the use of the anatomic "halo". However, currently subjective measures have been the standard when contouring the PET target volumes to be used with the CT target volumes.
Technology in Cancer Research & Treatment, Volume 8, Number 4, August 2009 An extensive literature in the area of PET/CT target definition has been developed for lung cancer treatment (12) (13) . Although the role of head and neck PET-CT has expanded from initial use in staging workup to the current state of incorporation in IMRT planning, comparatively few efforts have been undertaken to quantify head and neck PET tumor definitions. One pilot study (14) which reported patients planned for theoretical treatment that allowed PET-defined volumes to be a part of the target volume had the limitation of not having a valid or consistent way to interpret the PET images for treatment planning. A later study from the same group (15) attempted to make the PET interpretation more objective, using corrections for tissue concentrations of FDG, and adjusting for injected dose versus bodyweight. The results were more readily clinically applicable, with the identification of cervical lymph node disease and pathologic correlation from neck dissection specimens. A later effort reemphasized the variability encountered when interpreting PET-CT's for radiotherapy planning (16). Two neuro-radiologists and two radiation oncologists independently contoured the GTV; when the CT and PET volumes were drawn separately, variation between the volumes was found to be quite significant.
One approach to reduction of this variability involves the familiar 'anatomic halo.' The use of the 'halo' has been reported in both non-small cell lung cancer and head and neck cancers (17, 18) . Measurement of the halo in terms of SUV resulted in an observed range of 2.0 ± 0.4. However, there is still considerable inter-observer variability when volumes were constructed based on manually contouring the halo edge.
Despite the fact that many methods of using PET technology to delineate the GTV exist, there has yet to be a consensus approach reached amongst radiation oncologists. Efforts have been made to reduce inter-observer variability by PET volume segmentation based on a selected SUV or percent maximum threshold, but the technology to actually perform this task has yet to surface in practical clinical settings. In our study, we have taken steps to improve the objectivity of the integration of PET for GTV definition. Using customized auto-contouring software in combination with using the conformality index (CI), we measured the goodness of fit of a given PET iso-intensity level with the GTV defined on PET (GTV PET ) and with the GTV defined on CT (GTV CT ).
Materials and Methods
Use of the patient database for this study was approved by our Institution Review Board. Patients with pathologically confirmed squamous cell carcinoma of the head and neck region without gross resection of tumor were identified -all were treated definitively with chemoradiation. Characteristics of the twenty patients having complete initial pre-treatment imaging datasets (pretreatment PET scan, treatment planning CT scan, and contoured primary tumor volumes and lymph node volume structures) available are presented in Table I. The PET-CTs used in the study were performed in our radiology department, where standard guidelines for FDG dose, administration, and image acquisition were observed. FDG PET/CT scans were performed approximately 60-90 minutes following the intravenous injection of 15 mCi (555 MBq) of F-18 fluoro-deoxyglucose. Scans from the skull vertex to the proximal thighs were acquired on state-of-the-art fullring detector PET/CT cameras, and images were processed using iterative reconstruction. DICOM data (including images and structure sets) from the scans were then transferred to our custom software program (Velocity Medical Solutions, Atlanta, GA). Features of this system, which are demonstrated in Figure 1 , are (1) the ability to perform registration of the PET-CT and treatment planning CT using multiple viewing orientations, (2) the ability to obtain PET SUV statistics within a user-selected bounding box, and (3) the ability to generate contours based on iso-SUV level or maximum intensity thresholding.
For each patient, GTV PET was delineated by the radiation oncologist using visual estimation of window and level; similarly GTV CT was also delineated manually by the radiation oncologist. One novel aspect of our technique, as discussed in the above description of Figure 1 , relates to the definition of the GTV defined analytically (i.e., not manually) based only on the iso-SUV level. This quantity is termed GTV PET-ISO. An iso-intensity method was developed to automatically segment a GTV PET-ISO volume over a range of SUV levels (1.5 to 10) using two methods: (a) absolute SUV level and (b) %max intensity threshold. For each value of intensity, GTV PET-ISO was compared to GTV PET using the conformality index (CI) (12), which is measure the degree of intersection as a percentage of the union between the GTV constructed by the PET-CT and the GTV drawn from subjective means compared to auto-segmentation. Specifically, CI PET = B / (A+C B); where A = volume of GTV PET-ISO , C = volume of GTV PET , and B = volume of intersection of GTV PET-ISO and GTV PET . Similarly, GTV PET-ISO was compared to GTV CT by computing CI CT (replacing GTV PET with GTV CT in the above equation for CI PET ). The software tool automatically computed the CI for a range of intensity values. In each case, the peak CI, the optimum iso-SUV level, and optimum percent maximum intensity threshold were compared between CT and PET using the paired t-test (19).
A nuclear medicine physician used the auto-segmentation (i.e., GTV PET-ISO ) method alone for defining tumor volumes. These volumes were compared with those defined by the radiation oncologist. Specifically, the iso-SUV level and the %max threshold obtained by the radiation oncologist and nuclear medicine physician were compared using the paired t-test (19). Figure 2 shows plots of the conformality index for GTV PET compared with GTV PET-ISO as a function of (a) absolute SUV level, and (b) percent max SUV. In each case, for each patient, a characteristic curve was seen, with a peak conformality index correlating to a specific SUV. Table II summarizes the volume and CI comparisons. Table II (a) shows the absolute volumes of GTV CT , GTV PET , and GTV PET-ISO (note that the last column of this table represents GTV PET-ISO based on the absolute iso-SUV level, not percent max SUV). The peak CI, the absolute SUV level at which this peak CI occurred, and the percent max SUV level at which the peak CI occurred are summarized for the population in Table II (b) -note that in each case the entry for CI was computed using the iso-SUV (not percent max SUV) and represents the CI mean ± standard deviation over the study population. Also shown in Table  II (b) are the corresponding peak CI, absolute SUV level, and %max SUV for the GTV CT compared with GTV PET-ISO (note: the characteristic curves for this comparison are not shown in Figure 2 ). Table II(b) also shows p-values for the paired t-test comparisons of these quantities. As shown, the peak CI level was different using PET vs CT, but the absolute SUV and the % maximum threshold at which this peak occurred were not significantly different. Figure 3 displays the results of the comparison of the (a) iso-SUV level and (b) percent max SUV between the radiation oncologist and nuclear medicine physician. As shown, the radiation oncologists' volumes on average corresponded to a lower iso-SUV (3.02 ± 0.58 vs 4.36 ± 0.77, p < 0.001) and lower %Max SUV (24.1 ± 9.1% vs 34.3 ± 11.2%, p < 0.001) than those drawn by the nuclear medicine physician.
Results

Discussion
Efforts have been made to quantify PET visualization parameters in the context of treatment planning. In the early development of using PET-CT technology for radiotherapy planning, the majority of data came from non-small cell lung cancer studies. Along with having better discrepancy between atelectasis and tumor, PET-guided PTV's were altered significantly when compared to plans generated with CT alone (4-13). Success was met with the use of 40% of the max SUV threshold or an absolute SUV of 2.5, with the general notion that these are reasonable values in the setting of lung cancer when interpreted by nuclear medicine physicians. As SUV and percent max threshold have relative advantages and disadvantages, the lung cancer literature continued to explore the relationship between the GTV PET and GTV CT , notably using the conformality index (12). A similar concordance index was used for comparing volumes created by autodelineation, involving source-to-background ratios (SBR) versus direct visualization (13).
Our study can be viewed as a continuation of these latest efforts in lung cancer. Our results demonstrate the feasibility of implementing an iso-contouring method in an effort to reduce inter-observer variability in definition of GTV's for head and neck cancer. These results can be interpreted as a way to quantify the manner in which PET-CT can be used to guide treatment planning. We implemented an iso-SUV auto-contouring tool into treatment planning that is based on knowledge that the chosen SUV correlates with the gross tumor volume. From Table II(b), that the peak conformality index was significantly different between the PET and CT (an expected finding, given that the iso-SUV's are generated on the PET scan), but the other measures (iso-SUV and percent maximum SUV at which this peak CI occurred) were not, suggests that the iso-SUV approach can be used to define a reasonably consistent volume across the two imaging modalities. Though it may be suggested from the data in Table II (b) that the contours GTV PET and GTV CT which were manually drawn by the radiation oncologist are each best represented by the similar SUV-based iso-contours, it can not be determined from our study whether this is a reflection of observer-related consistency or modality-related consistency. As similar conclusions (23, 24), our study is the first to provide the CI characteristic curves over a population (Figure 2 ) and the first to explore comparison of radiation oncologist versus nuclear medicine physician-defined volumes (Figure 3 ).
Knowledge that a higher iso-SUV level results in smaller volumes can be used to better understand the treatment planning process. Commonly in clinical practice, when PET volumes are fused to the CT volumes, the final GTV is frequently modified. An enlargement of the volume usually occurs, due to the generous nature of subjective contouring along with suboptimal accuracy of treatment planning CT and PET registration. Iso-SUV based contouring may permit reduction in the overall size of the target without compromising tumor dose coverage; this is particularly important in head and neck cancer because this is a disease site more amenable to target localization (when compared with lung cancer and associated challenges with regard to respiratory gating). A future direction of our work is the potential for using a high iso-SUV level to define a boost volume for dose escalation.
In addition to showing that iso-SUV contouring is a tool for better understanding target definitions, one novel component of the current investigation is the use of iso-SUV contouring as a tool to compare the role of PET as a diagnostic test with its role in radiotherapy treatment planning. It was not The radiation oncology volumes on average corresponded to a lower iso-SUV (3.02 ± 0.58 vs 4.36 ± 0.77, p < 0.001) and lower %Max SUV (24.1 ± 9.1% vs 34.3 ± 11.2%, p<0.001) than those drawn by the nuclear medicine physician.
surprising that volumes defined by the radiation oncologist were larger (i.e., iso-SUV level was lower) when compared with those defined by the nuclear medicine physician. For the radiation oncologist, the practice of including areas of disease risk most likely influences the way in which the appropriate volume is selected for treatment planning. In contrast, the nuclear medicine physician interprets the PET images from a diagnostic standpoint. This emphasizes an inherent challenge in functional imaging, namely defining where the tumor ends and the normal tissue begins. The difference in percentage maximum threshold between radiation oncology and nuclear medicine (24% vs 34%) in our study is a starting point to understanding many aspects of visual interpretation and image pixel resolution when defining head and neck target volumes. For instance, the results of this study may reflect stylistic differences with regard to adjustment of the display thresholds (as the size of a target can be made larger or smaller, within a certain range, through such adjustments). In this vein, the iso-SUV / iso-percent max SUV technique could be used to create a family of iso-contours to assist the physician in 'bounding' a manually drawn target contour. Similarly, the iso-contour(s) generated using iso-SUV levels can be used as a starting point for manual contouring in the same manner as anatomic atlases are used at a number of disease sites for which radiotherapy is administered. Additionally, thresholds for true dimensions of lesions are size-dependent and therefore variable, and other factors such as motion or cystic/necrotic components of lesions also affect the accuracy of SUV calculations -differences in interpretation based on these and other parameters may account for some of the differences seen between radiation oncology and nuclear medicine physicians. Notably, however (and as displayed in Figure 3 ) although the average iso-SUV and %MaxSUV were different between the nuclear medicine and radiation oncology doctors, the dispersions (as measured by the standard deviations), were actually fairly similar, suggesting consistency across physician specialty. In this context, a problem also arises with target localization and the subsequent accuracy of PET / CT registration. Although many efforts have been undertaken to improve this registration, including the implementation of hybrid PET-CT / multimodality simulation (11, 19, 20) , many of the same problems of visual interpretation and tumor delineation will still be present even with exact registration.
There is not yet a standard way for integrating PET into head and neck radiation treatment planning. In this investigation we explore the role of iso-SUV contouring, and propose this method as an advance over earlier methods of windowleveling, visual halos, background subtraction, and absolute SUV cutoffs (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (20) (21) (22) . Although we have shown that iso-SUV contouring may assist with more objective definition of volumes, as Figure 2 shows there is still considerable variation in the optimum SUV level between patients. We do feel that, however, (in a manner similar to that for anatomic atlases which are being increasingly integrated into the radiotherapy treatment planning process for normal structures) that the iso-SUV contour for a population can be used as an objective starting point for individualized patient contours. One important future direction to our current work is to expand the study to explore the issue of inter-observer variability. The current study was restricted to one observer each from radiation oncology and from nuclear medicine.
To conduct a meaningful investigation of whether our technique reduces inter-observer variability would require several expert observers in the head and neck arena, ideally at several institutions. Notably, the software platform upon which this current work is done is being introduced to national radiotherapy clinical trials organizations which will facilitate exploring the hypothesis that our technique reduces inter-observer variability. Another future direction of the work is the pathologic correlation of the volumes obtained using different auto-contouring methods and different observers. Also, if tumor is defined more accurately and consistently, the efficacy of treatment (local control and other cancer control endpoints) may improve. Also, if the target defined using iso-SUV based contouring is consistently drawn more distantly from avoidance structures, then there might be an impact on toxicity endpoints as well.
The clinical impact of changes to target definition using our technique needs to be assessed in a large patient cohort, ideally in the clinical trial setting. With the current investigation, however, we feel we have taken initial steps to develop a consistent standard of contouring PET volumes in an effort to reduce the inter-observer variability in head and neck radiation treatment planning.
In conclusion, we demonstrated the feasibility of implementing PET iso-contouring as one step to improve the objectivity of GTV definition in head and neck cancer patients. Iso-SUV's can also be used to study the differences between PET's role as a nuclear medicine diagnostic test versus a radiation oncology treatment planning tool.
